PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Close to half of Americans can’t afford a one-bedroom rental: report

Show Me

Social Media’s Threat to Religious Freedom

Show Me

Lies, Lies and More Lies To Create Covid-19 Fear For Power and Money | The Texas Tribune ‘Corrects’ It’s Claim That 5,800 Children Hospitalized In 7 Days

Show Me

Minneapolis GOP campaign manager, PAC founder allegedly sex trafficked minors

Show Me

Chicago Cardinal Pushes for Mandatory Coronavirus Vaccines

Show Me

Hassan Mahmood on how the mindsets of successful people differ from others

Show Me

Fintech CEO Sentenced to 6 Years in Prison for COVID-19 Relief Loan Fraud, Investment Fraud

Show Me

Horatio Sanz groomed, sexually assaulted underage fan at ‘SNL’ party: lawsuit

Show Me

How the woke takeover of child services endangers abused kids

Show Me

Ex-Chicago police officer gets year in prison for taking bribes in exchange for crash report details

Show Me

VIDEO: New Yorkers Celebrate Cuomo Resignation, Tell DeBlasio ‘We Coming For You Next, We On Yo Ass Boy’

Show Me

WHO Scientist Says Chinese Pressured Investigation Team to Drop Lab-Leak Theory

Show Me

COVID-19, The Color Revolution, The Intelligence Branch and Over a Decade of Test Nudges

Show Me

ICE Freezes Enforcement for Crime Victims

Show Me

Meng Wanzhou Part of a ‘Coordinated Plan’ to Mislead HSBC: Lawyer

Show Me

The number of white people in America has declined for the first time since 1790

Show Me

Head’s Up: This US House Bill Would Require You be Vaccinated to Fly

Show Me

NY Supreme Court Sides With Project Veritas, Allows Group To Depose The New York Times

Show Me

Facebook to build $800M data center in metro Phoenix

Show Me

University Vaccine Mandate Stays as Justice Barrett Rebuffs Plea

Show Me

The Vaccinated Are Making The World Sick, According To The CDC | “Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021”

Show Me

To The Dismay Of Main Stream Media, They Now Admit Covid Vaccination Does Not Prevent The Spread Of Covid | “Vaccinated People With Breakthrough Infections Can Spread The Delta Variant, CDC Says” | NPR

Show Me

Rand Paul on NIH chief’s mask-at-home remark: How can smart people ‘say such stupid things?’

Show Me

Boston Mayor Indicates Opposition to Vaccine Passports, Comparing Them to Slave Papers

Show Me

Anthony Fauci Suggests Delta Variant Cases May Double, ‘Even If We Vaccinated Everyone Today’

Show Me

Coronavirus Spreading Among the Vaccinated in Highly Vaccinated Countries

Show Me

Lockdown-Critical Academics Get ‘Canceled’ | Video: 4 Minutes 05 Seconds

Show Me

Bosnia’s Peace Envoy Imposes Jail Terms for Genocide Denial

Show Me

Most Pro Athletes Shun Role of ’Public Spokesperson’ on COVID Vaccines

Show Me

Deadly drug-resistant ‘superbug’ now spreading in 2 cities, CDC says

Show Me

Big Ten will let individual schools decide on COVID-19 protocols

Show Me

U.S. businesses and municipalities weigh vaccine mandates as N.Y.C.’s mayor calls for companies to require shots.

Show Me

Female artist-scientist is named a finalist for one of the eight seats on SpaceX flight to the moon

Show Me

Concerned About BlackRock Pricing Out Home Buyers? Wait Until You Hear How Connected They Are To The Government

Show Me

mRNA Vaccine Inventor, Dr. Robert Malone, Says What’s Happening With The Covid-19 Vax is ‘Fundamentally Different’ | Video: 5 Minutes 50 Seconds

Show Me

Larry Elder Wins Calif. Ballot Lawsuit; Pelosi Rejects 2 GOP Picks for Jan. 6 Panel | Video: 19 Minutes 22 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 22, 2021 | Video: 48 Minutes 25 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 22, 2021 | Video: 48 Minutes 16 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded July 22, 2021 | Video: 48 Minutes 58 Seconds

Show Me

Biden Education Department Says It Was an ‘Error’ to Push CRT Activist Handbook

Show Me